Tracer library / [225Ac]Ac-90-NM600

[225Ac]Ac-90-NM600

Also written as Ac-225-NM600

Radionuclide: Ac-225 t½ 14284.8 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Brain metastases Breast cancer Lung cancer Melanoma Prostate cancer Immune cell and immunotherapy imaging

What it is

Compound class: DOTA-conjugated alkylphosphocholine (tumor-targeting phospholipid ether analog)
Target / mechanism: Alkylphosphocholine analog that preferentially accumulates in most tumor types via tumor cell membrane lipid rafts, semiselectively delivering the radioisotope to the tumor microenvironment PMID 34261797
Clinical application: Prostate cancer (metastatic castration-resistant), radiopharmaceutical therapy PMID 41319721
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	>90%	—	NM600	41319721 2026 Int J Radiat Oncol Biol Phys We performed radiolabeling of NM600 with 177Lu or 225Ac as follows: (10 μg per mCi for 177Lu and 100 μg per mCi for 225Ac) in 0.1 M NaOAc buffer (pH 5.5) for 30 minute at 90 °C. - Radiolabeling yield was above 90% for both isotopes

Need this precursor?We can point you to suppliers for [225Ac]Ac-90-NM600, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 34383787: 'NM600 (18-(4-(2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)phenyl)octadecyl) phosphate (NM600)'. Stage set/updated at stage 39 from PMID 41319721: 'NM600 was radiolabeled with 177Lu and 225Ac for radiopharmaceutical therapy studies in immunocompetent mice.'.